Holistic Management: Integrating Lifestyle, Supplements, and Monitoring

The Comorbidity Challenge
Gout rarely exists in isolation; 65% of patients have hypertension, 40% diabetes, and 30% CKD. The 2019 EULAR guidelines emphasize a “treat-to-target” approach combining urate-lowering therapy (ULT) with comorbidity management.
BISPIT’s Ecosystem Approach

1. Uric Acid Reducing Type 3310: Targets overproduction via xanthine oxidase inhibition.
2. GOUT RELIEF 3310 A+: Enhances excretion with renal-safe diuretics.
3. GOUT ATTACK 3310: Rapid relief for acute flares.
   Economic Impact
   A 2024 cost-effectiveness analysis found that BISPIT users incurred 30% lower annual healthcare costs versus conventional therapy cohorts, driven by reduced hospitalizations and drug-related complications.